Statin therapy in patients with chronic kidney disease: to use or not to use.
Standard
Statin therapy in patients with chronic kidney disease: to use or not to use. / Steinmetz, Oliver; Panzer, Ulf; Stahl, Rolf A.K.; Wenzel, Ulrich.
In: EUR J CLIN INVEST, Vol. 36, No. 8, 8, 2006, p. 519-527.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Statin therapy in patients with chronic kidney disease: to use or not to use.
AU - Steinmetz, Oliver
AU - Panzer, Ulf
AU - Stahl, Rolf A.K.
AU - Wenzel, Ulrich
PY - 2006
Y1 - 2006
N2 - Dyslipdemia is a common complication of chronic kidney disease (CKD) and contributes to high cardiovascular morbidity and mortality of CKD patients. Experimental studies have demonstrated that lipids induce glomerular and tubulointerstitial injury and that lipid-lowering treatments ameliorate renal injury. Therapy with statins not only has the potential to lower cardiovascular morbidity and mortality in patients with CKD but also to slow progression of renal disease. Whereas the guidelines for treatment of hyperlipidaemia in nonrenal patients are based on prospective, randomized, placebo-controlled mega-trials, such data are not available for CKD patients. This review outlines the limited information currently available on the effect of statins among patients with CKD and summarizes the ongoing randomized trials designed to address this question.
AB - Dyslipdemia is a common complication of chronic kidney disease (CKD) and contributes to high cardiovascular morbidity and mortality of CKD patients. Experimental studies have demonstrated that lipids induce glomerular and tubulointerstitial injury and that lipid-lowering treatments ameliorate renal injury. Therapy with statins not only has the potential to lower cardiovascular morbidity and mortality in patients with CKD but also to slow progression of renal disease. Whereas the guidelines for treatment of hyperlipidaemia in nonrenal patients are based on prospective, randomized, placebo-controlled mega-trials, such data are not available for CKD patients. This review outlines the limited information currently available on the effect of statins among patients with CKD and summarizes the ongoing randomized trials designed to address this question.
M3 - SCORING: Zeitschriftenaufsatz
VL - 36
SP - 519
EP - 527
JO - EUR J CLIN INVEST
JF - EUR J CLIN INVEST
SN - 0014-2972
IS - 8
M1 - 8
ER -
